Detalles de la búsqueda
1.
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.
Clin Infect Dis
; 78(4): 983-990, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37633256
2.
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2.
J Hepatol
; 2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38583491
3.
A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'.
J Hepatol
; 77(1): 245-248, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35358614
4.
Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.
Z Gastroenterol
; 57(5): 584-592, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31083746
5.
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.
Br J Clin Pharmacol
; 84(5): 961-971, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29345798
6.
Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
Liver Int
; 37(9): 1304-1313, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28135777
7.
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.
Liver Int
; 35(2): 448-54, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25319731
8.
Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.
J Hepatol
; 61(5): 976-83, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24946280
9.
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.
Hepatology
; 58(6): 1897-906, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24382638
10.
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure.
J Hepatol
; 58(3): 488-94, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23183521
11.
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
Gut
; 61(10): 1473-80, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22387529
12.
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.
Antivir Ther
; 27(3): 13596535221093856, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35695169
13.
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
Drug Saf
; 44(2): 133-165, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33141341
14.
Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France.
Hepatology
; 50(5): 1351-9, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19676130
15.
Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study.
Infect Dis Ther
; 6(2): 265-275, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28477061
16.
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.
PLoS One
; 12(1): e0168713, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28056030
17.
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).
PLoS One
; 11(7): e0158526, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27428331
18.
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.
PLoS One
; 10(9): e0138503, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26398503
19.
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study
Liver int
; 35(2): 448-454, Feb. 2015.
Artículo
en Inglés
| SES-SP, SESSP-IIERPROD, SES-SP | ID: biblio-1017141
20.
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Gastroenterology
; 131(4): 1040-8, 2006 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17030174
Resultados
1 -
20
de 20
1
Próxima >
>>